Value through Innovation
Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
Explore our content
-
BI Office Hours
Who we are
Boehringer Ingelheim invites innovative biomedical start-ups and entrepreneurs to join the next BI Office Hours at the Research Institute of Molecular Pathology (IMP). This is a great opportunity to benefit from BI’s science and business know-how.
-
PRESS RELEASE
Growth in all business areas, Operating performance improves to 1,555.4 million euros
-
PRESS RELEASE
Sharp increase in net sales to nearly 18.1 billion euros
-
PRESS RELEASE
Allcyte collaborates with Boehringer Ingelheim to advance preclinical oncology drug discovery by using novel drug response profiling technology
-
PRESS RELEASE
Positive results for the first half of 2017: Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for currency effects